40796-97-2 Usage
Uses
Used in Pharmaceutical Industry:
3-TROPANYL-3,5-DICHLOROBENZOATE is used as an anti-emetic agent for the treatment of nausea and vomiting. Its mechanism of action involves the modulation of specific receptors in the body, which helps to alleviate the symptoms associated with these conditions.
Used in Neurological Research:
In the field of neurological research, 3-TROPANYL-3,5-DICHLOROBENZOATE is utilized to study the role of SR-3 receptors. Studies have suggested that the blockade of SR-3 with 3-TROPANYL-3,5-DICHLOROBENZOATE may ameliorate beta-amyloid protein-induced neurotoxicity. This is achieved by interfering with the increase of calcium ions (Ca2+), subsequently inhibiting glutamate release, the generation of reactive oxygen species, and caspase-3 activity. This research is crucial for understanding the potential therapeutic applications of 3-TROPANYL-3,5-DICHLOROBENZOATE in the treatment of neurodegenerative diseases.
Used in Behavioral Neuroscience:
3-TROPANYL-3,5-DICHLOROBENZOATE is also used in the study of dopamine elevation in rats due to cocaine and amphetamine consumption. This research is vital for gaining insights into the mechanisms underlying the effects of these substances on the brain and for developing potential treatments for addiction and related disorders.
Originator
Bemesetron,Merrel Dow
Manufacturing Process
Tropine (34.24 g) is treated with anhydrous diethyl ether and ethereal
hydrogen chloride and the precipitated hydrochloride is isolated by
evaporation of the solvent. 3,5-Dichlorobenzoylchloride (51.7 g) is added and
the mixture stirred at 140°C for 15 minutes during which time the mixture
liquifies, evolves hydrogen chloride gas and resolidifies. After heating for a
further 15 minutes the cooled solid is dissolved in water, an excess of an
aqueous solution of potassium carbonate is added, and the base is extracted
with ethyl acetate. Evaporation of the dried ethyl acetate solution yields a
solid, which is recrystallized from aqueous methanol to yield 3,5-
dichlorobenzoic acid 8-methyl-8-aza-bicyclo[3.2.1]oct-1-yl ester (endo). MP:
95°C (51.8 g).
Therapeutic Function
Serotonin antagonist
Biological Activity
5-HT 3 antagonist.
Check Digit Verification of cas no
The CAS Registry Mumber 40796-97-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 4,0,7,9 and 6 respectively; the second part has 2 digits, 9 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 40796-97:
(7*4)+(6*0)+(5*7)+(4*9)+(3*6)+(2*9)+(1*7)=142
142 % 10 = 2
So 40796-97-2 is a valid CAS Registry Number.
InChI:InChI=1/C15H17Cl2NO2/c1-18-12-2-3-13(18)8-14(7-12)20-15(19)9-4-10(16)6-11(17)5-9/h4-6,12-14H,2-3,7-8H2,1H3/t12-,13+,14+
40796-97-2Relevant academic research and scientific papers
Synthesis of tropeines and allosteric modulation of ionotropic glycine receptors
Maksay, Gabor,Nemes, Péter,Biró, Tímea
, p. 6384 - 6391 (2007/10/03)
Twenty esters of 3α- and 3β-hydroxy(nor)tropanes and two amides of 3α-aminotropane were prepared with substituted benzoic acids. These (nor)tropeines inhibited [3H]strychnine binding to glycine receptors in synaptosomal membranes of rat spinal cord. A ternary allosteric model was applied to determine the dissociation constants (KA) of the tropeines having strong negative cooperativities with [3H]strychnine binding (α > 10). KA values about 10 nM are well below those of known allosteric agents. Low concentrations (0.1KA) of the (nor)tropeines potentiated the displacing effects of glycine. Positive cooperativity with glycine (β1) decreased with the increase in concentration and binding affinity of tropeines. Displacing potencies were also measured for [3H]granisetron binding to 5-HT3 type serotonin receptors of rat cerebral cortex. Selectivities to glycine receptors versus 5-HT3 receptors varied within 4 orders of magnitude. Nortropeines might serve as a lead to high-affinity selective allosteric modulators of glycine receptors.
Treatment of migraine with substituted tropyl benzoate derivatives
-
, (2008/06/13)
Migraine is treated with a tropyl benzoate derivative of the following general formula: STR1 wherein: R1 represents C1 -C4 alkyl, C1 -C4 alkoxy or halogen; R2 represents hydrogen, C1 -C4 alkyl, C1 -C4 alkoxy or halogen; and R3 represents hydrogen, C1 -C4 alkyl, C1 -C4 alkoxy or halogen, provided that R3 is hydrogen when R2 is hydrogen, or a pharmaceutically acceptable salt thereof. Additionally, some novel tropyl benzoate derivatives are disclosed.
Treatment of migraine with substituted tropyl benzoate derivatives
-
, (2008/06/13)
Migraine is treated with a tropyl benzoate derivative of the following general formula: STR1 wherein: R1 represents C1 -C4 alkyl, C1 -C4 alkoxy or halogen; R2 represents hydrogen, C1 -C4 alkyl, C1 -C4 alkoxy or halogen; and R3 represents hydrogen, C1 -C4 alkyl, C1 -C4 alkoxy or halogen, provided that R3 is hydrogen when R2 is hydrogen, or a pharmaceutically acceptable salt thereof. Additionally, some novel tropyl benzoate derivatives are disclosed.
